Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.…
Poolbeg Pharma PLC (GB00BKPG7Z60.SG) Seasonal returns chart
Poolbeg Pharma (LON: POLB) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 15 employees.
The shares were at 6.150 GBp on 20 November 2026, up 70.8% over 52 weeks. Its 52-week range is 3.300 GBp to 9.300 GBp: the price is 33.9% below the high and 86.4% above the low.
Its market capitalisation is 43.36M GBP.
Poolbeg Pharma reports return on equity of -66.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 4.82M GBP. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 19.00 GBp is 208.9% above the current price.
No upcoming events tracked.